Fig. 5: THOR-707 induced the expansion of peripheral, intratumoral and splenic CD8⁺ T and NK cells in B16-F10 tumor-bearing C57BL/6 mice.

a Percentage of CD8⁺ memory T cells within the CD3⁺ T cell population up to 10 days post-dose of a single 1 or 3 mg/kg intravenous bolus dose of THOR-707 to tumor-bearing mice. Bars represent an average from 4 replicates at each time point (except n = 7 for 3 mg/kg at days 3, 5, 7), shown as individual points. *p < 0.05, ***p < 0.001 using unpaired, non-parametric t-test. b Ratio of CD8⁺ T cell vs. CD4⁺ Treg cells in the peripheral blood following administration of a single 1 or 3 mg/kg intravenous bolus dose of THOR-707 to B16-F10 tumor-bearing mice. Bars represent an average from 4 replicates at each time point (except n = 7 for 3 mg/kg at days 3, 5, 7), shown as individual points. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired, non-parametric t-test. c Percentage of NK cells in CD3⁻ T, CD8⁺ T and Treg cells in the tumor CD3⁺ T cell population following treatment with a single 1 or 3 mg/kg intravenous bolus dose of THOR-707. Tumor samples were analyzed for immune cell populations 5 days after treatment by FACS (data represented for day 5). Bars represent an average from 4 replicates at each time point (except n = 7 for 3 mg/kg at days 3, 5, 7), shown as individual points. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired, non-parametric t-test. d Percentage of NK cells in CD3⁻ cells, CD8⁺ T and Treg cells in the spleen CD3⁺ T cell population following treatment with a single 3 mg/kg intravenous bolus dose of THOR-707. Spleen samples were analyzed for immune cell populations 5 days after treatment by FACS. Bars represent an average of 4 replicates at each time point shown. *p < 0.05, **p < 0.01, ***p < 0.001 using unpaired non-parametric t-test. Source data are provided as a Source Data file.